Investing where biology
meets software
Neuralink sits at the intersection of biology and software,
with clinical progress that could redefine medicine — and,
eventually, how humans interact with technology.
Neuralink's devices are already implanted in human participants, with the potential to restore function for people living with paralysis.
The brain–computer interface platform extends far beyond a single product — into neurology, rehabilitation and consumer computing.
Decades-long clinical and regulatory development creates a barrier to entry that few competitors could replicate.
Success in either direction — medical or consumer — would redefine a category we already hold for the long term.
Founded in 2016
BCI platform pioneer
100% privately held equity
Why Neuralink is a core
holding in our portfolio.
A clinical breakthrough
First-generation implants already in human trials,
with the potential to restore function for people
living with paralysis.
A platform technology
A brain–computer interface platform that extends far
beyond one device, into neurology and consumer
computing.
A durable moat
Decades-long regulatory and clinical development creates
a barrier that compounds with every new approval,
protecting long-term value.
Access the world's best
private companies with us
Private markets reward patient capital. Join us in backing the founders
building the defining companies of the next generation.